Tesamorelin in 2026 Q2: what changed

The second quarter of 2026 produced exactly one new clinical result for tesamorelin, and it was a null one. On 17 June 2026 a double-blind, placebo-controlled pilot trial in eNeurologicalSci reported that 10 weeks of low-dose tesamorelin in 22 adults, whose baseline cognition ranged from normal to mild cognitive impairment, was not linked with significant changes on the study's measures.^[1] Everything else about the drug's standing held still between 1 April and 30 June. The US label did not change, the EU still has no authorised product, and no new trial was registered.

The one new result was a null result

The trial gave 1 mg of tesamorelin or placebo for 10 weeks and looked at body composition, fatigue, sleep, physical performance, glucose tolerance, cognitive function and brain imaging. The authors' own summary sentence is the one to carry: "Low-dose GHRH treatment was not directly linked with significant changes in study measures."^[1] They then ran machine learning models over the imaging data and reported possible treatment-related differences in the right anterior cingulate and the left superior frontal occipital fasciculus, framing the work as evidence that pairing cognitive tests with neuroimaging picks up smaller signals.^[1] That is a finding about method, not a cognitive benefit.

Scale is the thing to hold on to. Twenty-two people, ten weeks, a pilot design, and a registration number (NCT02553603) that dates the underlying study well before this quarter.^[1] Cognition is one of the two research directions people most often attach to tesamorelin when they argue for use outside the approved indication. A small trial that failed to move its own endpoints is not a reason to become more confident about that argument.

Three reviews, one consistent placement

The quarter's other publications were reviews rather than results, and they agreed with each other. On 12 April 2026 Sports Medicine published a narrative review by Mendias and Awan covering AOD-9604, BPC-157, CJC-1295, follistatin-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, elamipretide, tesamorelin (Egrifta), thymosin beta-4 and TB-500. Its framing sets approved drugs against what it calls a parallel gray market of unapproved compounds "operating largely outside of regulatory oversight," and it notes that rigorous human safety data for the unapproved group is scarce.^[3]

On 18 June 2026 a group at Poznan University of Medical Sciences published a longer review in Frontiers in Endocrinology on peptides sold as "research compounds" that act on the growth hormone and IGF-1 axis. It sorts those peptides into evidence tiers and puts tesamorelin at the top of the pile, describing it as having "RCT evidence and FDA-approved indication (HIV-associated lipodystrophy); off-label uses unproven."^[2] On the safety side it records the growth-hormone-axis worry in careful language: "Mitogenic GH/IGF-1 signalling (theoretical oncologic concern); no established clinical carcinogenic signal."^[2] Mitogenic here means promoting cell division, which is the mechanism behind the theoretical cancer question that follows this whole drug class.

With the singular exception of tesamorelin within its approved HIV-lipodystrophy indication, none of these compounds carry regulatory approval for performance- or appearance-related use

The third item appeared in Clinical Infectious Diseases on 15 May 2026: two case reports of adults with well-controlled HIV and excess visceral abdominal fat, one treated with tesamorelin and one who received a GLP-1 receptor agonist before tesamorelin was added.^[4] The clinical point is reasonable, that visceral fat can persist independently of body mass index and may not respond to a general weight-loss drug. The provenance deserves a flag. Two of the four authors are employees of Theratechnologies, the company behind Egrifta, and two others declare speaker honoraria from it.^[4] Two patients described by people with a commercial interest is the weakest evidence design of the quarter.

What the label still says

None of that changed the approved use. The Egrifta WR prescribing information on DailyMed states that the product "is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy," and lists contraindications including disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity and pregnancy.^[5] The label also specifies IGF-1 monitoring during treatment and says to consider stopping the drug where IGF-1 stays elevated.^[5] Two of its limitations of use answer questions readers ask us directly: "Long-term cardiovascular safety of EGRIFTA WR has not been established," and "EGRIFTA WR is not indicated for weight loss management."^[5]

In Europe the position is unchanged and older. The EMA record shows that on 21 June 2012 Ferrer Internacional notified the CHMP that it wished to withdraw the marketing-authorisation application for Egrifta, and the committee's concerns at the time included the clinical meaningfulness of the effect and raised IGF-1 levels.^[6] Nothing was refiled in Q2 2026. Readers in the EU, EEA and UK are therefore looking at an unlicensed medicine, and the regulatory section of our tesamorelin page sets out what that means in practice.

The vendor side of the quarter

One FDA peptide warning letter fell inside the window. On 17 June 2026 the agency wrote to Wholesale Peptide of Brooksville, Florida, about Prostamax and Gonadorelin, and it did not name tesamorelin.^[8] The reasoning still travels. FDA wrote that "Despite statements on your product labeling marketing your products for, 'RESEARCH USE ONLY' and 'not for human consumption,'" the labeling and website established that the products were intended as drugs for human use.^[8]

Two months after the quarter closed the agency did name it. In a letter dated 24 August 2026 to Peak Performance Peptides, FDA listed "Bac water," retatrutide, semaglutide, SS-31, PT-141 and tesamorelin as unapproved new drugs under section 505(a), and warned that injectable products "bypass some of the body's key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions."^[9] That letter sits outside Q2, and we are flagging it because it is the next thing a reader of this quarter needs.

What we still do not know

No tesamorelin study was first posted to the international registry between 1 April and 30 June 2026. A ClinicalTrials.gov query filtered to that date range returns a total count of zero.^[7] So the liver and metabolic question, the one that keeps tesamorelin in the fatty-liver conversation, gained no new trial in the quarter. Neither did the cognition question, beyond the small pilot above.^[1]

The honest read is that Q2 2026 clarified the boundary rather than moving it. Tesamorelin remains the one growth-hormone-axis peptide with a real approval attached to it, and that approval covers one population and one endpoint.^[2] If you are weighing it for anything else, the material published this quarter argues for more caution, not less. Take that question to a clinician who knows your history, and see our United States regulation page for the jurisdictional picture.